Physician profile
Peter D Ennis
NPI 1508893926
$6,384.03
in general payments reported to CMS, 2019-2025
63 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $487 · 2021: $287 · 2022: $387 · 2023: $972 · 2024: $857 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,722.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $648.95 | 2019-2024 | Opdivo, Camzyos, Eliquis |
| Shield Therapeutics INC | $527.63 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $351.68 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Pfizer INC. | $346.95 | 2019-2025 | |
| Abbvie INC. | $328.98 | 2019-2025 | |
| Celgene Corporation | $320.26 | 2019-2024 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $278.48 | 2019-2025 | |
| Genzyme Corporation | $227.58 | 2020-2025 | |
| Janssen Biotech, INC. | $226.85 | 2019-2025 | Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $194.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $167.69 | 2019-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $165.01 | 2019-2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Eisai INC. | $144.45 | 2019-2025 | |
| Daiichi Sankyo INC. | $142.77 | 2020-2025 | Datroway, Enhertu |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $125.00 | 2019 | |
| Blueprint Medicines Corporation | $111.05 | 2023-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $105.33 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.08 | 2020-2025 | Fruzaqla, Iclusig, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $99.37 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $99.11 | 2021-2025 | |
| Amgen INC. | $85.54 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Astellas Pharma US INC | $75.63 | 2019-2023 | Padcev, Xospata |
| Incyte Corporation | $73.07 | 2024-2025 | Monjuvi, Pemazyre, Zynyz |
| Seagen INC. | $72.32 | 2019-2022 | |
| Kite Pharma, INC. | $66.11 | 2020-2023 | Yescarta |
| Genmab U.S., INC. | $64.70 | 2024-2025 | Tivdak, Epkinly |
| Glaxosmithkline, LLC. | $62.38 | 2023-2025 | Ojjaara, Shingrix |
| Adc Therapeutics America, INC. | $59.85 | 2023-2025 | |
| Emd Serono, INC. | $54.85 | 2019-2025 | |
| Beone Medicines USA, INC. | $52.47 | 2025 | Brukinsa, Tevimbra |
| Sumitomo Pharma America, INC. | $51.66 | 2024-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $51.64 | 2022-2025 | Ultomiris |
| Gilead Sciences, INC. | $49.70 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $47.05 | 2024-2025 | Orserdu |
| Sobi, INC | $39.61 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $38.92 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $37.93 | 2022-2023 | Xpovio |
| Tersera Therapeutics LLC | $34.84 | 2022-2025 | Zoladex |
| Spectrum Pharmaceuticals INC. | $33.97 | 2023-2025 | Rolvedon |
| Exelixis INC. | $32.72 | 2022-2025 | Cabometyx |
| Caris Mpi, INC. | $31.25 | 2025 | Mi Cancer Seek |
| Aveo Pharmaceuticals, INC. | $27.21 | 2023 | Fotivda |
| Amneal Pharmaceuticals LLC | $25.61 | 2024 | Avastin |
| Janssen Pharmaceuticals, INC | $25.08 | 2019 | |
| Lilly USA, LLC | $24.58 | 2025 | Verzenio, Jaypirca |
| Morphosys, US INC. | $23.26 | 2023 | Monjuvi |
| Verastem, INC. | $21.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.13 | 2019 | |
| Springworks Therapeutics, INC. | $19.12 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $18.55 | 2025 | Romvimza, Qinlock |
| Mirati Therapeutics, INC. | $18.12 | 2024 | Krazati |
| Azurity Pharmaceuticals, INC. | $17.48 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $17.44 | 2023 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $17.33 | 2025 | Tevimbra |
| Array Biopharma INC | $17.31 | 2024 | Mektovi, Lorbrena, Braftovi |
| Mylan Institutional INC. | $17.25 | 2020 | |
| Pharmacosmos Therapeutics INC. | $17.20 | 2025 | Monoferric |
| Tactile Systems Technology INC | $15.49 | 2020 | |
| Puma Biotechnology, INC. | $14.84 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.18 | 2019 | |
| Advanced Accelerator Applications | $13.51 | 2020 | |
| Aurobindo Pharma USA, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.